Sleep Disturbances and Their Association With Quality of Life in Older Psychiatric Patients During the COVID-19 Pandemic

Xiuying Xu1,*, Wen Li2,3,4,* , Siyun Zou5,*, Yulong Li6,*, Huan Wang6,*, Xiaona Yan1, Xiangdong Du5, Lan Zhang6, Qinge Zhang7,*, Teris Cheung8, Gabor S. Ungvari9,10, and Yu-Tao Xiang2,3,4

Abstract

Aims: The negative effect of the COVID-19 pandemic on sleep quality of clinically stable psychiatric patients is unknown. This study examined the prevalence of sleep disturbances and their association with quality of life (QOL) in clinically stable older psychiatric patients during the COVID-19 pandemic. Methods: This multicenter, cross-sectional study involved older patients attending maintenance treatment at outpatient departments of four major psychiatric hospitals in China. Patients’ socio-demographic and clinical characteristics were collected. Sleep disturbances, depressive symptoms, and QOL were assessed with the Insomnia Severity Index, the 9-item Patient Health Questionnaire, and 2 items of the World Health Organization Quality of Life-Brief version, respectively. Binary logistic regression analysis was conducted to examine the independent associations of socio-demographic and clinical variables with sleep disturbances, while the association between sleep disturbances and QOL was explored with analysis of covariance. Results: A total of 941 patients were recruited. The prevalence of sleep disturbances was 57.1% (95% CI: 53.9–60.2%). Analysis of covariance revealed that QOL was significantly lower in patients with sleep disturbances compared to those without. Multivariate logistic regression analysis showed that sleep disturbances were positively and independently associated with more severe depressive symptoms (OR = 1.32, 95% CI: 1.26–1.37). Compared to patients with major depressive disorder, those with other psychiatric diagnoses had a significantly higher prevalence of sleep disturbances (OR = 1.44, 95% CI: 1.00–2.08). Conclusion: Sleep disturbances were common among clinically stable older psychiatric patients during the COVID-19 pandemic. Considering the negative association with QOL, this subpopulation needs regular assessment and timely treatment to reduce their sleep disturbances and improve their QOL.

1Department of Psychiatry, Xiamen Xianyue Hospital, Xiamen, China
2Faculty of Health Sciences, Unit of Psychiatry, Department of Public Health and Medicinal Administration, and Institute of Translational Medicine, University of Macau, Macao SAR, China
3Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China
4Institute of Advanced Studies in Humanities and Social Sciences, University of Macau, Macao SAR, China
5Guangji Hospital Affiliated to Soochow University, Suzhou, China
6Department of Psychiatry, Lanzhou University Second Hospital, Lanzhou, China
7The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders Beijing Anding Hospital, The Advanced Innovation Center for Human Brain Protection, School of Mental Health, Capital Medical University, Beijing, China
8School of Nursing, Hong Kong Polytechnic University, Hong Kong SAR, China
9Division of Psychiatry, School of Medicine, University of Western Australia/Graylands Hospital, Perth, Australia
10University of Notre Dame Australia, Fremantle, Australia

Received 6/23/2021. Received revised 8/18/2021. Accepted 8/23/2021.

*These authors contributed equally to the work

Corresponding Authors:
Dr. Yu-Tao Xiang, I/F, Building E12, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau SAR, China.
Email: xyutly@gmail.com

Dr. Qinge Zhang, Beijing Anding Hospital of Capital Medical University, Beijing, China.
Email: zq881@126.com
Keywords
older patients, psychiatric disorder, sleep disturbances, quality of life, COVID-19

Introduction
The Coronavirus Disease 2019 (COVID-19) was first reported in China at the end of 2019, and subsequently was found in over 200 countries.\(^1\) Compared to the general population, psychiatric patients are arguably one of the most vulnerable subpopulations affected by the COVID-19 outbreak. Psychiatric patients have a higher risk of contagion due to their sedentary lifestyle, limited awareness of self-protection, and non-adherence to preventive public health measures.\(^2\) In addition, patients with psychiatric disorders, such as major depressive disorder (MDD), schizophrenia, and bipolar disorder, require long-term treatment. Due to the under-developed community mental health services in China, clinically stable patients need to regularly attend psychiatric outpatient departments located in urban hospitals for maintenance treatment.\(^3,4\) Traveling during the outbreak of any infectious disease inevitably increases the risk of infection. A significant proportion of patients had difficulties attending their psychiatric outpatient appointments due to quarantine and traffic restrictions for prevention and control of the COVID-19 outbreak.\(^5\) These public health preventive measures interrupted treatment leading to relapse and undesirable behaviors such as self-harm and aggression.

Among those individuals affected by the COVID-19 outbreak, special attention should be given to older psychiatric patients. Compared with other age groups, older adults infected with COVID-19 have poor treatment outcomes and higher mortality rates.\(^6,7\) Older adults are have fear of COVID-19, which could worsen their pre-existing mental health problems.\(^8\) Patients with MDD and anxiety disorder are exceptionally vulnerable.\(^9\) Most mental health services and education related to the COVID-19 (e.g., psycho-education and psychological counseling) are primarily delivered online.\(^10\) Thus, many older psychiatric patients could not benefit from these online services due to their limited access to smartphones and broadband internet, and poor digital health literacy.\(^8\)

Sleep disturbances constitute a major health problem worldwide.\(^11\) During the COVID-19 outbreak, sleep disturbances were found to be very common in the general population\(^12\) and subpopulations, such as frontline clinicians\(^13\) and patients with COVID-19.\(^14\) However, to the best of our knowledge, no study has focused on older adults, especially those with psychiatric disorders. Sleep disturbances are associated with treatment with psychotropic medications,\(^15\) impaired cognitive function,\(^16\) increased risk of psychiatric disorders\(^17\) and cardiovascular and metabolic diseases,\(^18\) poor quality of life (QOL),\(^19\) increased consumption of health care services, and economic burden.\(^20\) Sleep disturbances are also risk factors for deterioration and relapse of psychiatric disorders.\(^17\) In order to reduce the negative impact of sleep disturbances on health outcomes and daily life, it is important to understand their patterns and associated factors.

Quality of life is a standard health outcome, which reflects individuals’ general perception on their physical and mental health.\(^21,22\) Thus, this study examined the prevalence of sleep disturbances and their association with QOL in a sizeable cohort of clinically stable older psychiatric patients.

Methods
Participants
This was a cross-sectional study conducted between May 22 and June 23, 2020, in four major tertiary psychiatric hospitals located in the northern (Beijing), southern (Fujian province), eastern (Jiangsu province), and western parts (Gansu province) of China. All older patients attending outpatient departments of the four psychiatric hospitals for maintenance treatment were consecutively invited to participate in the study. To be eligible, patients should be: (1) aged 50 years and above; (2) have a principal diagnosis of any type of psychiatric disorders diagnosed according to the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) confirmed by their treating psychiatrists; (3) clinically stable judged by their treating psychiatrists. Following previous studies\(^23,24\) patients with changes in doses of psychotropic medications of less than 50% in the past three months were considered “clinically stable.” This criterion has been used in clinical practice in the participating hospitals; and (4) able to give written informed consent. Patients who had difficulty understanding the survey’s content, such as those with dementia, were excluded. The study protocol was approved by the Ethics Committees of the Xiamen Xianyue Hospital, Guangji Hospital Affiliated to Soochow University, Lanzhou University Second Hospital, and Beijing Anding Hospital.

Measurements
Participants’ basic socio-demographic and clinical data were collected including age, gender, marital status, education, and current severe medical conditions affecting
the cardiovascular, respiratory, digestive, hematological, endocrine, urinary, connective tissue, and nervous systems. Three additional COVID-19 related questions were also asked, namely, whether participants were concerned about the COVID-19 outbreak during the past months, whether they had difficulty attending psychiatrists during the COVID-19 pandemic, and whether they had difficulty attending psychiatric hospitals/departments during the COVID-19 pandemic.

The severity of depressive symptoms was evaluated with the Chinese version of the 9-item Patient Health Questionnaire (PHQ-9). Each item of the PHQ-9 is scored from 0 (“not at all”) to 3 (“nearly every day”). This scale has been validated in Chinese populations. The total score of PHQ-9 that ranges between 0 and 27 was calculated by adding up all its item scores. The PHQ-9 total score of ≤5, ≥5, and ≥10 indicated “no depressive symptoms,” “mild depressive symptoms,” and “moderate to severe depressive symptoms,” respectively. The severity of sleep disturbances was assessed with the 7-item Insomnia Severity Index (ISI), a Likert scale with each item between 0 and 4. The ISI has satisfactory psychometric properties in China. The ISI total score ranges from 0 to 28, with higher total scores representing more severe sleep disturbances. The cutoff value of ≥8 was considered as the presence of some form of “sleep disturbances.” The aggregate score of the two items on the overall QOL of the World Health Organization Quality of Life-Brief Version (WHOQOL-BREF) was used to evaluate patients’ QOL. The QOL score range between 0 and 10, with a higher score representing higher QOL.

**Data Analysis**

All data analyses were performed with the Statistic Package for Social Science (SPSS), Version 24.0. The normality of continuous variables was examined with the Kolmogorov–Smirnov test. Socio-demographic (age, gender, marital status, education) and clinical characteristics (severe medical diseases, concerns about the COVID-19 outbreak, difficulties attending psychiatrists and/or attending psychiatric hospitals/departments, principal psychiatric diagnoses, and severity of depressive symptoms) were compared between patients with and without sleep disturbances. Normally distributed continuous variables were compared with the two independent samples t-tests, while variables that did not follow normal distribution were compared using Mann–Whitney U tests. Categorical variables were compared using χ² tests. Independent associations of socio-demographic and clinical variables with sleep disturbances were examined applying binary logistic regression analysis with the “enter” method. All socio-demographic and clinical variables were entered as independent variables, and the presence of sleep disturbances was the dependent variable. The QOL between patients with and without sleep disturbances was compared using analysis of covariance (ANCOVA) after controlling for variables with significant group differences in univariate analyses. The level of significance was set at P < .05 (two-tailed).

**Results**

A total of 946 patients were invited to participate in the study; 941 met the eligibility criteria, yielding a response rate of 99.5%. The mean age of participants was 62.9 (Standard Deviation (SD)): 9.4) years and 32.4% (n = 305) were men. The prevalence of sleep disturbances was 57.1% (95% confidence interval (CI): 53.9–60.2%). The mean ISI total score was 8.94 (SD: 6.30). The prevalence of no, mild, and moderate to severe depressive symptoms was 37.4% (95% CI: 34.3–40.5%), 32.7% (95% CI: 29.7–35.7%), and 29.8% (95% CI: 26.9–32.7%), respectively.

Univariate analyses revealed that participants with sleep disturbances were younger (P = .02), had shorter education (P < .01) and higher PHQ-9 total scores (P < .01). The prevalence of sleep disturbances was significantly different across the principal psychiatric diagnoses (P < .01). There was no significant difference in the prevalence of sleep disturbances between male and female patients (58.0% (95% CI: 52.4–63.6%) vs 56.6% (95% CI: 52.7–60.4%), χ² = .17, P = .68). Binary logistic regression analysis found that the presence of sleep disturbances was positively and independently associated with more severe depressive symptoms (P < .01, OR = 1.32, 95% CI: 1.26–1.37). Compared to participants with MDD, those with other psychiatric diagnoses were more likely to have sleep disturbances (P = .04, OR = 1.44, 95% CI: 1.00–2.08) (Table 1). ANCOVA revealed that participants with sleep disturbances had a significantly lower overall QOL compared to those without them (F (1, 941) = 18.10, P < .01).

**Discussion**

This study investigated the prevalence of sleep disturbances in clinically stable older psychiatric patients (≥50 years) and their association with QOL during the COVID-19 outbreak in China. Over half (57.1%, 95% CI: 53.9–60.2%) of the participants suffered from sleep disturbances, which is higher than the corresponding figures reported in other populations using the same measure and cutoff value during the COVID-19 outbreak, such as frontline clinicians (28.75–38.4%), 36–38 psychiatric inpatients with COVID-19 (42.8%), 14 breast cancer patients (36.2%), 39 and the general population (28.5%). 40 The prevalence of sleep disturbances in this study was also much higher than the figures in both the general population...
Table 1. Participants’ socio-demographic and clinical characteristics and their associates with sleep disturbances.

| Variables                                      | Total (N=941) | No sleep disturbances (N=404) | Sleep disturbances (N=537) | Univariate analyses | Multivariate logistic regression<sup>3</sup> |
|------------------------------------------------|---------------|-------------------------------|----------------------------|---------------------|---------------------------------------------|
|                                                | N  | %   | N  | %   | N  | %   | χ² | df | P   | OR  | 95% CI | P   |
| Gender                                         | N  | %   | N  | %   | N  | %   |    |    |     |     |       |     |
| Female                                         | 636 | 67.6 | 276 | 68.3 | 360 | 67.0 | .17 | 1  | .68  | Ref | —     | —   |
| Male                                           | 305 | 32.4 | 128 | 31.7 | 177 | 33.0 |     |    |      | 1.10 | .77–1.56 | .58 |
| Married                                        | 847 | 90.0 | 367 | 90.8 | 480 | 89.4 | .54 | 1  | .46  | .68  | .38–1.22 | .19 |
| Severe medical conditions<sup>1</sup>           | 172 | 18.3 | 73  | 18.1 | 99  | 18.4 | .21 | 1  | .89  | 1.12 | .69–1.80 | .62 |
| Concern about the COVID-19 outbreak            | N  | %   | N  | %   |     |     | .84 | 2  | .66  |     |       |     |
| None                                           | 405 | 43.0 | 170 | 42.1 | 235 | 43.8 |     |    |      |     |       |     |
| Sometimes                                      | 353 | 37.5 | 150 | 37.1 | 203 | 37.8 |     |    |      | 1.04 | .71–1.52 | .83 |
| Frequently                                     | 183 | 19.4 | 84  | 20.8 | 99  | 18.4 |     |    |      | 1.02 | .63–1.63 | .93 |
| Difficulty attending psychiatrists             | 350 | 37.2 | 150 | 37.1 | 200 | 37.2 | <.01 | 1  | .97  | .80  | .53–1.21 | .30 |
| Difficulty attending psychiatric hospitals/departments | 352 | 37.4 | 138 | 34.2 | 214 | 39.9 | .39 | 1  | .07  | .79  | .52–1.20 | .28 |
| Principal psychiatric diagnosis<sup>2</sup>     | N  | %   | N  | %   | N  | %   | 14.13 | 3  | <.01 |     |       |     |
| Major depressive disorder                      | 433 | 46.0 | 179 | 44.3 | 254 | 47.3 |     |    |      |     |       |     |
| Schizophrenia                                  | 59  | 6.3  | 38  | 9.4  | 21  | 3.9  |     |    |      | .57  | .28–1.16 | .12 |
| Organic mental disorders                       | 57  | 6.1  | 29  | 7.2  | 28  | 5.2  |     |    |      | 1.21 | .58–2.53 | .60 |
| Other psychiatric diagnoses                    | 392 | 41.7 | 158 | 39.1 | 234 | 43.6 |     |    |      | 1.44 | 1.00–2.08 | .04 |
| Age (years)                                    | Mean | SD  | Mean | SD  | Mean | SD  | Z    | P    |
| 62.89                                          | 9.43 | 63.71 | 9.57 | 62.28 | 9.29 | -2.31 | —    | .02  | .99  | .97–1.01 | .85 |
| Education (years)                              | 7.90 | 4.01 | 8.36 | 3.96 | 7.56 | 4.01 | -4.21 | —    | <.01 | .99  | .95–1.04 | .89 |
| PHQ-9 total score                              | 7.66 | 6.63 | 3.82 | 4.36 | 10.55 | 6.58 | -16.72 | —    | <.01 | 1.32 | 1.26–1.37 | <.01 |
| Quality of life                                 | 6.20 | 1.54 | 6.82 | 1.44 | 5.72 | 1.43 | -11.39 | —    | <.01 |     |       |     |

<sup>1</sup> Current severe medical disease affecting the cardiovascular, respiratory, digestive, hematological, endocrine, urinary, connective tissue, and nervous systems.

<sup>2</sup> Only psychiatric diagnoses with the percentage >5% are presented separately; those with percentage of <5% were included in “others”.

<sup>3</sup> The independent variables were all socio-demographic and clinical variables: age, gender, marital status, education years, severe physical diseases suffering, concerns about the COVID-19 outbreak, difficulty attending psychiatrists, difficulty attending psychiatric hospitals/departments, principal psychiatric diagnoses, and PHQ-9 total score and study sites that were controlled, while the dependent variable was sleep disturbances.

Bold values: <.05.

Abbreviations: COVID-19 = Coronavirus Disease 2019; CI = Confident Interval; MDD = major depressive disorder; PHQ-9 = 9-item Patient Health Questionnaire; Ref = reference group; SD = standard deviation.
(15.0%, 95% CI: 12.1–18.5%) in China before the COVID-19 outbreak, although measures on sleep disturbances were different.

The reasons for the high frequency of sleep disturbances in older psychiatric patients are complex. Psychiatric disorders and sleep disturbances often co-exist because sleep rhythm changes in many psychiatric disorders as well as with the use of psychotropic medications. Besides, age is a risk factor for sleep disturbances such as insomnia. In older adults, sleep and circadian rhythm changes occur along with the physiologic changes, presenting as gradually decreased sleep efficiency and total sleep time. Unrealistic expectations about sleep duration and quality could elevate the risk of sleep disturbances. Moreover, increased prevalence of medical conditions (e.g., nocturia and physical disability) and treatment (e.g., beta-blockers, glucocorticoids, and non-steroidal anti-inflammatory drugs) also contributes to the occurrence of sleep disturbances. Aging women including those with psychiatric disorders are more likely to suffer from sleep disturbances than men. However, no gender difference was found in the current study, probably because of the increased prevalence of sleep disturbances in both genders during the COVID-19 outbreak, which may have offset the gender difference reported earlier.

The COVID-19 outbreak was associated with increased risk of sleep disturbances in older psychiatric patients for several reasons. First, more severe consequences including higher mortality rates in older adults with COVID-19 spread fear and psychological distress. Second, quarantine measures lead to loneliness, fatigue, and daytime sleepiness and thus affect sleep and circadian rhythm. Third, older psychiatric patients have frequent comorbid chronic medical conditions and require long-term medication. Difficulties in attending hospitals during the COVID-19 outbreak further aggravated patients’ distress about the discontinuation of treatment and further contributed to the development of sleep disturbances.

As expected, patients with sleep disturbances reported more severe depressive symptoms in this study. The association between sleep disturbances and depressive disorders is bidirectional: sleep disturbances are risk factors of depressive disorders, while depression increases the likelihood of sleep disturbances. In meta-analyses, sleep disturbances significantly predicted the onset of depressive episodes with an overall odds ratio (OR) of up to 2.83 (95% CI: 1.55–5.17). Another study found that sleep deprivation can negatively influence the brain areas that process emotionally salient information, such as amygdala and the medial-prefrontal cortex, which are associated with increased risk of depressive symptoms. Furthermore, the association between sleep disturbances and depressive symptoms might be related to shared pathomechanisms, for example, similar alterations of arousal state and in the level of inflammatory markers. In this study, patients with other psychiatric diagnoses, mainly schizophrenia and organic mental disorders, were more likely to suffer from sleep disturbances than those with MDD. The diagnostic heterogeneity makes it difficult to interpret the reasons for the unexpectedly significant group difference. Head-to-head comparative studies between different psychiatric diagnoses with respect to sleep disturbances are warranted to replicate or refute this finding.

Patients with sleep disturbances had a lower overall QOL than those without sleep disturbances, which is consistent with previous findings. According to the distress/protection QOL model, QOL is determined by the interaction between protective (e.g., good social support and economic status) and distressing factors (e.g., poor health). Sleep disturbances are associated with impaired daytime functioning, attention deficits, and impairment of working memory and executive functions, poor physical health, and psychiatric symptoms all of which could lower QOL.

The strengths of this study include the multicenter study design and the large sample size. However, several methodological limitations need to be addressed. First, the study only included clinically stable patients, which limits the generalizability of the findings to patients at different stages of their illness. Second, due to logistical reasons related to the COVID-19 outbreak, clinical stability was judged by the treating psychiatrists, rather than assessed by standardized rating instruments. Third, the causal relationships between demographic and clinical characteristics and sleep disturbances could not be examined due to the cross-sectional study design. Fourth, other factors potentially associated with sleep disturbances (e.g., use of sedative-hypnotics, level of social support, and economic status) and COVID-19-related factors (e.g., having relatives/friends infected with COVID-19) were not examined in this study.

In conclusion, sleep disturbances were common in clinically stable, older psychiatric patients during the COVID-19 outbreak. Given the potentially negative impact of sleep disturbances on QOL and daily functioning, regular assessment of sleep duration and quality should be given particular attention in the routine clinical care of this vulnerable population. A variety of treatment modalities, such as cognitive-behavioral therapy, repetitive transcranial magnetic stimulation, neurofeedback, promotion of sleep hygiene and sleep medications are available and should be offered to patients presenting with sleep disturbances.

Acknowledgments

The authors are grateful to all participants and clinicians involved in this study.
Author Contributions

Study design: QZ, Y-TX. Data collection, analysis and interpretation: XX, WL, SZ, YL, HW, XY, XD, LZ, QZ. Drafting of the article: WL, TC, Y-TX. Critical revision of the article: GSU. Approval of the final version for publication: all co-authors.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Universidade de Macau grant number MYRG2019-00066-FHS, Suzhou Key Medical Center for Psychiatric Diseases grant number Szzx201509, The National Science and Technology Major Project for investigational new drug grant number 2018ZX09201-014 and the Beijing Municipal Science and Technology Commission grant number Z181100001518005.

Data Availability Statement

The Clinical Research Ethics Committee of participating hospitals that approved the study prohibits the authors from making the research dataset of clinical studies publicly available. Readers and all interested researchers may contact Dr YT Xiang (Email address: xyutly@gmail.com) for details. Dr Xiang will apply to the Clinical Research Ethics Committee of participating hospitals for the release of the data.

ORCID iDs

Wen Li https://orcid.org/0000-0002-6722-0804
Qinge Zhang https://orcid.org/0000-0002-0095-1995
Yu-Tao Xiang https://orcid.org/0000-0002-2906-0029

References

1. World Health Organization. WHO Coronavirus disease (COVID-19) dashboard; 2020. https://covid19.who.int/. Accessed June 22, 2020.
2. Zhu Y, Chen L, Ji H, Xi M, Fang Y, Li Y. The risk and prevention of Novel Coronavirus pneumonia infections among inpatients in psychiatric hospitals. Neurosci Bull. 2020;36(3):299-302.
3. Xiang YT, Ng CH, Yu X, Wang G. Rethinking progress and challenges of mental health care in China. World Psychiatr. 2018;17(2):231-232.
4. Xiang Y-T, Yu X, Sartorius N, Ungvari GS, Chiu HF. Mental health in China: challenges and progress. Lancet. 2012;380(9855):1715-1716.
5. Li W, Yang Y, Liu Z-H, et al. Progression of mental health services during the COVID-19 outbreak in China. Int J Biol Sci. 2020;16(10):1732-1738.
6. Shahid Z, Kalayanamirthi R, McClafferty B, et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020;68(5):926-929.
7. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524.
8. Yang Y, Li W, Zhang Q, Zhang L, Cheung T, Xiang YT. Mental health services for older adults in China during the COVID-19 outbreak. Lancet Psychiatr. 2020;7(4):e19.
9. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100-106.
10. Liu S, Yang L, Zhang C, et al. Online mental health services in China during the COVID-19 outbreak. Lancet Psychiatr. 2020;7(4):e17-e18.
11. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.
12. Kokou-Kpolou CK, Megalakaki O, Laimou D, Kousouri M. Insomnia during COVID-19 pandemic and lockdown: prevalence, severity, and associated risk factors in French population. Psychiatr Res. 2020;290:113128.
13. Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-907.
14. Wang Y, Zhu L-Y, Ma Y-F, et al. Association of insomnia disorder with sociodemographic factors and poor mental health in COVID-19 inpatients in China. Sleep Med. 2020;75:282-286.
15. Bajaj V, Kalra I, Bajaj A, Sharma D, Kumar R. A case of zolpidem dependence with extremely high daily doses. Asia Pac Psychiatr. 2019;11(4):e12356.
16. Koo DL, Shin J-H, Lim J-S, Seong J-K, Joo EY. Changes in circadian misalignment due to insomnia, lack of sleep, and shift work in increasing the risk of cardiac diseases: a systematic review. Cureus. 2020;12(1):e6616.
17. Khan S, Malik BH, Gupta D, Rutkofsky I. The role of circadian misalignment due to insomnia, lack of sleep, and shift work in increasing the risk of cardiac diseases: a systematic review. Cureus. 2018;10(3):e1444.
18. Kyle SD, Morgan K, Espie CA. Insomnia and sleep-related quality of life. Sleep Med Rev. 2010;14(1):69-82.
20. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273.

21. Monson E, Caron J, McCloskey K, Brunet A. Longitudinal analysis of quality of life across the trauma spectrum. Psychol Trauma. 2017;9(5):605-612.

22. Gao K, Su M, Sweet J, Calabrese JR. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. J Affect Disord. 2019;244:9-15.

23. Xiang Y-T, Weng Y-Z, Leung C-M, Tang W-K, Ungvari GS, Gerevich J. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Prog Neuro Psychopharmacol Biol Psychiat. 2007;31(3):756-760.

24. Lobana A, Mattoo SK, Basu D, Gupta N. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand. 2001;104(1):51-55.

25. Xiang YT, Ma X, Lu JY, et al. Alcohol-related disorders in Beijing, China: prevalence, socio-demographic correlates, and unmet need for treatment. Alcohol Clin Exp Res. 2009;33(6):1111-1118.

26. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.

27. Chen M, Sheng L, Qu S. Diagnostic test of screening depressive disorder in general hospital with the patient health questionnaire (in Chinese). Chinese Mental Health. 2015;29(4):241-245.

28. Wang W, Bian Q, Zhao Y, et al. Reliability and validity of the Chinese version of the patient health questionnaire (PHQ-9) in the general population. Gen Hosp Psychiat. 2014;36(5):539-544.

29. Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiat. 2010;32(4):345-359.

30. Morin CM. Insomnia: Psychological Assessment and Management. New York: Guilford Press; 1993.

31. Bai C, Daihong J, Chen L, Liang L, Wang C. Reliability and validity of insomnia severity index in clinical insomnia patients (in Chinese). Chinese J Pract Nurs. 2018;34(28):2182-2186.

32. Smith MT, Wegener ST. Measures of sleep: the insomnia severity index, medical outcomes study (MOS) sleep scale, pittsburgh sleep diary (PSD), and pittsburgh sleep quality index (PSQI). Arthritis Care Res. 2003;49(S5):S184-S196.

33. Harper A, Power M, Grp W. Development of the world health organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551-558.

34. Fang JQ, Hao YA. Reliability and validity for chinese version of WHO quality of life scale (in Chinese). Chin Ment Health J. 1999;13(4):203-209.

35. Xia P, Li N, Hau K-T, Liu C, Lu Y. Quality of life of Chinese urban community residents: a psychometric study of the mainland Chinese version of the WHOQOL-BREF. BMC Med Res Methodol. 2012;12(1):37.

36. Que J, Shi L, Deng J, et al. Psychological impact of the COVID-19 pandemic on healthcare workers: a cross-sectional study in China. General Psychiatry. 2020;33(3):e100259.

37. Zhang W, Wang K, Yin L, et al. Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China. Psychoter Psychosom. 2020;89(4):242-250.

38. Zhang C, Yang L, Liu S, et al. Survey of insomnia and related social psychological factors among medical staff involved in the 2019 novel coronavirus disease outbreak. Front Psychiatr. 2020;11:306.

39. Li J, Augusto S-MC, Feng H, et al. Patient reported outcomes of breast cancer patients during the COVID-19 outbreak in the epicenter of China: a cross sectional survey study. Clin Breast Cancer. 2020;20(5):e651-e662.

40. Lin LY, Wang J, Ou-Yang XY, et al. The immediate impact of the 2019 novel coronavirus (COVID-19) outbreak on subjective sleep status. Sleep Med. 2020;77:348-354.

41. Cao X-L, Wang S-B, Zhong B-L, et al. The prevalence of insomnia in the general population in China: a meta-analysis. PLoS One. 2017;12(2):e0170772.

42. Zheng W, Luo X-N, Li H-Y, et al. Prevalence of insomnia symptoms and their associated factors in patients treated in outpatient clinics of four general hospitals in Guangzhou, China. BMC Psychiatr. 2018;18(1):232.

43. Krystal AD. Psychiatric disorders and sleep. Neurol Clin. 2012;30(4):1389-1413.

44. Higuchi T, Ishigooka J, Iyo M, Hagi K. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: results of a 26-week open-label extension study. Asia Pac Psychiatr. 2020;12(1):e12377.

45. Sonnega A, Leggett A, Pepin R, Assari S. Physical activity and insomnia symptoms over 10 years in a US national sample of late-middle-age and older adults: age matters. J Aging Phys Activ. 2020;1:1-10.

46. Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med: JCSM. 2018;14(6):1017-1024.

47. Foley DJ, Monjan A, Simonick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years. Sleep. 1999;22(suppl 2):S356-S372.

48. Griffin SC, Williams AB, Mladen SN, Perrin PB, Dzierzewska JM, Rybarczyk BD. Reciprocal effects between loneliness and sleep disturbance in older Americans. J Aging Health. 2019;32(9):1156-1164.

49. Um Min Allah N, Arshad S, Mahmood H, Abbas H. The psychological impact of coronavirus outbreak in Pakistan. Asia Pac Psychiatr. 2020;12:e12409.

50. Jaussent I, Bouyer J, Ancelin ML, et al. Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep. 2011;34(8):1103-1110.
51. Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev. 2019;43:96-105.
52. Sunderajan P, Gaynes BN, Wisniewski SR, et al. Insomnia in patients with depression: a STARD report. CNS Spectr. 2010;15(6):394-404.
53. Li L, Wu C, Gan Y, Qu X, Lu Z. Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. BMC Psychiatr. 2016;16(1):375.
54. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19.
55. Yoo S-S, Gujar N, Hu P, Jolesz FA, Walker MP. The human emotional brain without sleep—a prefrontal amygdala disconnect. Curr Biol. 2007;17(20):R877-R878.
56. Riemann D, Spiegelhalder K, Feige B, et al. The hyper-arousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010;14(1):19-31.
57. de Lecea L, Carter ME, Adamantidis A. Shining light on wakefulness and arousal. Biol Psychiatr. 2012;71(12):1046-1052.
58. Hein M, Lanquart J-P, Loas G, Hubain P, Linkowski P. Similar polysomnographic pattern in primary insomnia and major depression with objective insomnia: a sign of common pathophysiology? BMC Psychiatr. 2017;17(1):273.
59. Krysta K, Krzystanek M, Bratek A, Kroupka-Matuszczak I. Sleep and inflammatory markers in different psychiatric disorders. J Neural Transm. 2017;124(1):179-186.
60. Léger D, Scheuermayer K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med. 2001;63(1):49-55.
61. Berkley AS, Carter PA, Yoder LH, Acton G, Holahan CK. The effects of insomnia on older adults’ quality of life and daily functioning: a mixed-methods study. Geriatr Nurs. 2020;41:832-838.
62. Voruganti L, Heslegrave R, Awad AG, Seeman MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med. 1998;28(1):165-172.
63. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption. Pharmacoeconomics. 1998;14(6):629-637.
64. Fortier-Brochu E, Beaulieu-Bonneau S, Ivers H, MORIN CM. Insomnia and daytime cognitive performance: a meta-analysis. Sleep Med Rev. 2012;16(1):83-94.
65. Zhang J, Lam S-P, Li S, et al. Insomnia, sleep quality, pain, and somatic symptoms: sex differences and shared genetic components. Pain. 2012;153(3):666-673.
66. Carlbring P, Andersson G, Cuijpers P, Riper H, Hedman-Lagerlöf E. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. Cognit Behav Ther. 2018;47(1):1-18.
67. Song P, Lin H, Li S, et al. Repetitive transcranial magnetic stimulation (rTMS) modulates time-varying electroencephalography (EEG) network in primary insomnia patients: a TMS-EEG study. Sleep Med. 2019;56:157-163.
68. Luctkar-Flude MF, Tyerman J, Groll D. Exploring the use of neurofeedback by cancer survivors: results of interviews with neurofeedback providers and clients. Asia-Pacific J Oncol Nurs. 2019;6(1):35-42.
69. Myrto ST, Huhn M, Chiocchia V, et al. Efficacy, acceptability and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis. Acta Psychiatr Scand. 2020;142(1):6-17.